Clinical trials are testing for these effects, with early results indicating better blood sugar control and the potential to reduce the need for other diabetes drugs
Figure 31: Photograph of Professor Bernard Thorens, credit Center for Integrative Genomics, University of Lausanne
The advantage of in-person clinics is direct provider access and often more payment flexibility
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reduce appetite, slow digestion, and support blood sugar regulation
"Manufactured in the USA" refers to the processing, hydrolyzation, quality testing, and packaging - not the geographic origin of the bovine source material
Its main actions include: Stimulating insulin secretion from pancreatic beta cells in a glucose-dependent manner Suppressing glucagon release, which reduces hepatic glucose production Slowing gastric emptying, which moderates post-meal glucose spikes Promoting satiety through central nervous system pathways, thereby reducing appetite GIP is released by K-cells in the proximal small intestine and shares some functions with GLP-1, particularly in enhancing insulin secretion after meals
